SCHEMBL5260554

SCHEMBL5260554

CCOC(=O)c1csc2c1CCC2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.62
TP53 P04637 2/20 0.62
ALDH1A1 P00352 8/20 0.60
HPGD P15428 7/20 0.60
THRB P10828 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
TDP1 Q9NUW8 1/20 0.58
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
HTT P42858 2/20 0.53
SMN1; SMN2 Q16637 5/20 0.52
ALOX15 P16050 2/20 0.51
MAPK1 P28482 2/20 0.51
HSD17B10 Q99714 2/20 0.51
GAA P10253 2/20 0.51
KDM4E B2RXH2 1/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 2/20 0.51
USP2 O75604 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1379362 0.97 MAPT (0.65) MAPTTP53ALDH1A1HPGDTHRB
SCHEMBL23833453 0.95 MAPT (0.66) MAPTTP53ALDH1A1HPGDTHRB
SCHEMBL1425934 0.84 ADORA1 (0.50) MAPTTP53ALDH1A1HPGDTHRB
SCHEMBL2998220 0.83 ADORA1 (0.50) MAPTTP53ALDH1A1HPGDTHRB
SCHEMBL18430429 0.82 HPGD (0.58) MAPTTP53ALDH1A1HPGDTHRB
SCHEMBL31564318 0.81 MAPT (0.46) MAPTTP53ALDH1A1HPGDTHRB
SCHEMBL5358780 0.81 ALDH1A1 (0.54) MAPTTP53ALDH1A1HPGDTHRB
SCHEMBL13768422 0.80 MAPT (0.46) MAPTTP53ALDH1A1HPGDTHRB
SCHEMBL6318336 0.80 ADORA1 (0.59) MAPTTP53ALDH1A1HPGDTHRB
SCHEMBL4009963 0.80 MAPT (0.46) MAPTTP53ALDH1A1HPGDTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225318-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation BIOLIPOX AB (SE) 2007-09-27 US claimed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121030-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed
US-20070225318-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation BIOLIPOX AB (SE) 2007-09-27 US disclosed
EP-1794145-A1 PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2007-06-13 EP disclosed
WO-2006032851-A1 PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225318-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation ALOX15, ALOX15B, ALOX12 MAPT 4420/4885TP53 1108/4885ALDH1A1 306/4885
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D MAPT 66/4885TP53 20/4885ALDH1A1 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.